Both antibody based chimeric receptor and TCR-based allo-reactivity contribute to the antitumor response. (A) Preactivated allogeneic T cells (either transgenic T-bodies—Black-N29 or wild-type—Black) were incubated with Renca-Her2/neu-luciferase cells at the indicated ratios. Killing activity was quantified by measuring the bioluminescent signal after 24 hours (no killing was observed using Black cells at 1:1 and 5:1 ratios). (B) Preactivated allogeneic T cells (either transgenic T-bodies—Black-N29 or wild-type—Black) were incubated with Renca-Her2/neu cells, and thymidine incorporation was measured 24 hours later. (C) Kaplan-Meyer survival plots of Renca-Her2/Neu-bearing mice. Mice (n = 6/group) were irradiated with 200 rads, and 1 day later either left untreated as a control (blue diamond), or injected with 100 × 106 T cells. The T cell populations used were either: allogeneic mock transduced T cells (Black, empty black triangles, P = .0011 vs control), syngeneic T cells transduced with the N29 CAR (Balb-N29 Ts, filled purple squares), allogeneic T cells transduced with the N29 CAR (Black-N29 Ts, filled orange triangles, P = .0005 vs Black, P = .012 vs Balb-N29), syngeneic T cells from N29 transgenic Balb/c mice (Balb-N29 Tg, open pink squares, no significant difference was seen vs transduced cells), or allogeneic T cells from N29 transgenic C57BL/6 mice (C57BL-N29 Tg, open brown triangles, no significant difference was seen vs transduced cells).
